Common Contracts
2 similar License Agreement contracts by Clovis Oncology, Inc.
ContractLicense Agreement • May 5th, 2020 • New York
EX-10.1 7 d82988exv10w1.htm EX-10.1 Exhibit 10.1 Amended and Restated License Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (the “Agreement”) is made and entered into effective as of November 10, 2010 (the “Effective Date”) by and between Clavis Pharma ASA, a Norwegian company (“Licensor”), and Clovis Oncology, Inc., a Delaware corporation (“Licensee”). Licensor and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” RECITALS WHEREAS, Licensor and Licensee entered into that certain License Agreement, dated November 23, 2009, between the Parties (the “Existing Agreement”) whereby Licensor granted licenses under certain of its rights in North America, Central and South America and Europe to Licensee with respect to certain oral and intravenous formulations of CP-4126, a lipid ve
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • June 23rd, 2011 • Clovis Oncology, Inc. • New York
This Amended and Restated License Agreement (the “Agreement”) is made and entered into effective as of November 10, 2010 (the “Effective Date”) by and between Clavis Pharma ASA, a Norwegian company (“Licensor”), and Clovis Oncology, Inc., a Delaware corporation (“Licensee”). Licensor and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
